Embecta Business Summary

Embecta Corp. (EMBC) is a global medical technology company primarily focused on the manufacture and sale of insulin delivery solutions, generating revenue through the high-volume sale of consumables such as insulin pen needles, syringes, and safety injection devices. Spun off from Becton, Dickinson and Company (BD) in 2022, the company operates through a global footprint spanning over 100 countries, with core business segments divided into traditional insulin delivery devices and an emerging portfolio of GLP-1 delivery partnerships and digital diabetes management tools. As of early 2026, Embecta is executing a strategic pivot to become a broad-based medical supplies provider to offset secular pressures in the U.S. market. It competes directly with Novo Nordisk, Ypsomed, and Terumo in the injection space, while facing significant market-share competition from wearable pump manufacturers like Insulet and Tandem Diabetes; Embecta maintains a dominant position in the legacy injection market but is currently valued as a value-oriented turnaround play relative to its high-growth peers. The company is led by Chairman and CEO Devdatt (Dev) Kurdikar, who previously served as President of BD’s Diabetes Care business and CEO of Cardiac Science Corporation. The executive team includes CFO Jake Elguicze, formerly of Teleflex, and SVP of Strategy Ginny Blocki, who brings extensive experience from Baxter International. Jeffrey Z. Mann serves as SVP, General Counsel, and Head of Corporate Development, overseeing the company’s M&A and partnership initiatives. The board is anchored by Lead Independent Director Dr. Claire Pomeroy, President of the Lasker Foundation, and includes notable members such as former Integra LifeSciences CFO Carrie L. Anderson and former BD CFO Christopher R. Reidy. Embecta is characterized by high institutional ownership, with major stakes held by State Street Corporation, Charles Schwab Investment Management, and Pacer Advisors.